Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT01392326) enrolled 606 people in total — 202 in each of three groups. One group received a 75 mg dose of the study drug (secukinumab, also referred to as AIN457), one received a 150 mg dose, and one received a placebo (a dummy treatment with no active ingredient). The trial was primarily measuring how many participants showed a meaningful improvement in joint symptoms — specifically, at least a 20% improvement across several standard measures of joint pain, swelling, and overall disease activity (a standard benchmark known as "ACR20"). A number of secondary measurements were also taken, including skin symptom improvement (relevant to participants who also had psoriasis), changes in overall disease activity scores, physical functioning, and quality of life. The reported data shows that, for the primary measure (ACR20 joint improvement), around 50.5% of participants in the 75 mg group and 50.0% in the 150 mg group met that threshold, compared with 17.3% in the placebo group. For participants who had significant skin involvement from psoriasis, the reported data shows that 64.8% (75 mg group) and 61.1% (150 mg group) achieved a 75% reduction in their skin score (PASI75), compared with 8.3% in the placebo group; and 49.1% and 45.4% respectively achieved an even larger 90% skin score reduction (PASI90), compared with 3.7% in the placebo group. For the secondary measures, the reported data shows changes in overall disease activity scores, physical functioning scores, and daily activity scores were all numerically larger in both secukinumab groups than in the placebo group, though the scale and meaning of each of those measures differ. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 31943974) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Psoriatic Arthritis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male, or a female who is not pregnant and not breastfeeding, and you are at least 18 years old
- You have been diagnosed with Psoriatic Arthritis (PsA) using a specific set of medical criteria called CASPAR, your symptoms have been present for at least 6 months, and your condition is moderate to severe — with at least 3 tender joints and at least 3 swollen joints at the start of the trial
- You have tested negative for two specific markers (Rheumatoid factor and anti-CCP antibodies) that are checked in a blood test
- You have active plaque psoriasis, shown by at least one skin patch larger than 2cm, nail changes related to psoriasis, or a documented history of plaque psoriasis
Who may not be able to join:
- You have a chest X-ray showing signs of an active infection or cancer in the chest
- You have previously been treated with more than 3 different medications belonging to a group called TNFα inhibitors
- You are currently taking strong opioid painkiller medications
- You have ever received certain types of biologic (immune-system targeting) medications, except for those that target TNFα
- There may be additional criteria not listed here (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
2 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent of Patients Achieving ACR20 Response Criteria on Secukinumab 75 or 150 mg vs. Placebo
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.